The angiogenic microenvironment has been known to be a component of angioimmunoblastic T-cell lymphoma since its initial characterization. We have shown that angioimmunoblastic T-cell lymphoma endothelial cells produce vascular endothelial growth factor-A (VEGFA), and participate in lymphoma progression. In squamous cell carcinoma, endothelial BCL2 expression induces a crosstalk with tumor cells through VEGFA, a major mediator of tumoral angiogenesis. In the present study, we analyzed BCL2 and VEGFA in 30 angioimmunoblastic T-cell lymphomas, using triple immunofluorescence to identify protein coexpression in wellcharacterized lymphoma cells and microenvironment neoangiogenic endothelial cells. Using quantitative real-time PCR, we assessed mRNA expression levels in laser-microdissected endothelial and lymphoma cells. In lymphoma cells, as in endothelial cells, BCL2 and VEGFA proteins were coexpressed. BCL2 was expressed only in neoangiogenic CD34 þ CD105 þ endothelial cells. In laser-microdissected cells, mRNA studies showed a significant relationship between BCL2 and VEGFA levels in CD34 þ endothelial cells, but not in CD3 þ CD10 þ lymphoma cells, or in CD34 þ endothelial cells from lymph node hyperplasia. Further study showed that, in AITL, BCL2 mRNA levels in CD34 þ CD105 þ neoangiogenic endothelial cells also correlated with microvessel density, International Prognostic Index, Ann Arbor stage, bone marrow involvement and elevated LDH. BCL2 expression by CD105 þ neoangiogenic endothelial cells is related to tumor progression in angioimmunoblastic T-cell lymphoma.
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Hypoxia can also induce BCL2 expression in human aortic endothelial cells through p38 MAPK pathway. 10 In vitro, BCL2 expression is able to protect human dermal endothelial cells from apoptosis, independently of cytochrome c release, by increasing survivin expression, and inhibiting p53 and p38 MAPK accumulation. 11 Moreover, blocking BCL2 activity alters in vitro endothelial cell growth and tubular morphogenesis. 12 Neoangiogenic endothelial cells can be characterized in solid tumor by expression of CD105, a TGFbR type III auxiliary receptor. 13 In meningiomas, glioblastomas, and squamous cell carcinoma, CD105 expression on endothelial cells is related to neoangiogenesis and to tumor progression. [14] [15] [16] CD105 is also expressed by endothelial cells in the primary central nervous system lymphomas and correlates with survival. 17 Here, we studied BCL2 and VEGFA expression in neoangiogenic endothelial cells and lymphoma cells in angioimmunoblastic T-cell lymphoma.
Materials and methods

Patient Selection
In all, 30 patients with angioimmunoblastic T-cell lymphoma (14M/16F, 33-84 years, median 60 years) were included in this study. Histological diagnoses were established according to the WHO classification. 18 Induction chemotherapy was six cycles of CHOP and CHOP-like regimen followed by consolidation and maintenance chemotherapies as previously reported. 19 Eight age-and sex-matched patients with lymph node hyperplasia were referred as controls. Approval was obtained from the Institut Universitaire d 0 Hématologie-Hô pital Saint-Louis institutional review board. All patients gave their informed consent.
Tissue Specimen
Lymph nodes, surgically removed for diagnostic purpose, were immediately cut: one part was fixed in formaldehyde and further processed for paraffin embedding, another part was snap-frozen. Bone marrow biopsies were performed in all 30 patients with angioimmunoblastic T-cell lymphoma, and skin biopsies in 11 patients with angioimmunoblastic T-cell lymphoma with skin rash.
Microvessel Density
The microvessel density was evaluated by endothelial cell immunostaining with CD34 antibody (clone QBEnd10, Beckman Coulter). Angiogenesis assessment was based on the method of Weidner et al 20 and international consensus criteria for angiogenesis quantification. 21, 22 Microvessels were counted at Â 400 magnification on five different fields. The microvessel density of each specimen was calculated as the mean value of the different counts. Five normal lymph nodes were used as controls for microvessel density measurement.
MKI67 Labeling Index Assessment
MKI67 labeling index was assessed using mouse monoclonal MIB1 antibody (Dako, France) with an indirect immunoperoxidase method. MKI67 labeling index was calculated as the percentage of positive nuclei for MKI67 staining at Â 400 magnification on five different fields. In the case of heterogeneous staining, areas containing the largest and smallest number of positive cells were selected and the percentages were averaged to give the MKI67 labeling index.
Triple Immunofluorescent Labelings
Triple immunofluorescent labelings were performed to assess coexpression of BCL2/CD34/CD3 and BCL2/CD34/VEGFA. Tissue sections were analyzed by two different pathologists (AJ and PR) on a motorized Z-axis Olympus (Tokyo, Japan) BX 61 microscope. Microscopic pictures were captured through a UPlan Fl/ 40 Â /0.75 objective with a digital camera ColorView III using Olympus-SIS Cell F software.
Laser-Microdissection Combined to Molecular Analyses
Laser-microdissection was performed on 7 mm-thick lymph node frozen sections after immunofluorescent staining; after acetone post-fixation 5 min at 41C, sections were incubated for 5 min with antibodies bound to fluorophores, using Zenon kits (Invitrogen, France). CD34 antibody (clone QBEnd10, Beckman Coulter), CD105 (clone SN6h, Abcam), CD3 (rabbit polyclonal, Biocare Medical) were bound to Alexa 488, and CD10 (clone 56C6, Novocastra) to Alexa 594.
In the 30 angioimmunoblastic T-cell lymphoma lymph node sections, laser-microdissection was performed: (i) for lymphoma cells, identified as CD3 þ CD10 þ medium-sized cells, [23] [24] [25] (ii) for CD34 þ endothelial cells, and (iii) for CD105 þ neoangiogenic endothelial cells, on different successive frozen sections.
A quantitative assessment was achieved by PALM Robo software (Zeiss-Palm, Germany). For each patient, B500 CD3 þ CD10 þ lymphoma cells corresponding to an average surface of 170 000 mm 2 , 500 CD34 þ endothelial cells, and 500 CD105 þ neoangiogenic endothelial cells, corresponding to an average surface of 100 000 mm 2 , were microdissected and catapulted into tubes for RNA extraction.
In the eight lymph node hyperplasia frozen sections, laser-microdissection was performed to select: (i) for CD3 Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA). First-strand cDNA was synthesized using Superscript II reverse transcriptase (Invitrogen) according to the manufacturer's instructions.
Ascertainment of the specificity of laser-microdissected cells was systematically performed using quantitative real-time PCR:
CD34
þ -microdissected cells from angioimmunoblastic T-cell lymphoma and lymph node hyperplasia were considered as endothelial cells since they expressed CD31 mRNA but not CD3e or CD10 mRNA. CD3 þ CD10 þ -microdissected cells from angioimmunoblastic T-cell lymphoma were considered as lymphoma cells since they expressed CD10 mRNA but not CD31 mRNA. CD3
þ -microdissected cells from lymph node hyperplasia were considered as lymphocytes since they expressed CD3e but not CD31 mRNA.
Quantitative real-time PCR was performed on an ABI PRISM 7700 system using the Pre-Developed TaqMan Assay Reagent specific for human CD3e (Hs01062241_m1), CD10 (Hs00153510_m1), CD31 (Hs00169777_m1), BCL2 (Hs00608023_m1), and VEGFA (Hs00900055_m1), and for human transcription factor IID/TATA-binding protein (TBP) gene expression quantification (PE Applied Biosystems, UK). The TBP gene was used as an internal control. Results were quantified using the comparative cycle threshold (Ct) method. Jurkat and MCF7 cells, which respectively express the BCL2 and VEGFA genes, were used as calibrators. 3, 26 CD3e, CD10 and CD31 mRNA expressions were first assessed, to check the laser-microdissection selection of cell populations.
Statistical Analyses
Patient characteristics were compared using w 2 and Fisher's exact tests for categorical variables, and Wilcoxon's test for continuous variables. Event-free survival was calculated from the date of diagnosis to the date of progression, relapse, or death. Overall survival was measured from the date of diagnosis to either death from any cause or the stopping date of 1 January 2008. Survival rates were estimated using the Kaplan-Meier method and compared by logrank test. Multivariate survival analysis was performed using a Cox regression model. Difference were considered significant when the two-sided P-value was o0.05. Difference were considered significant when the two-sided P-value was o0.05. All statistical analyses were performed using SAS 8.2 software (SAS Institute, Cary, NC, USA).
Results
BCL2 Expression in AITL Endothelial Cells
Using two different methods, multiple fluorescent immunostainings for BCL2 and CD34 (Figure 1) , and laser-microdissection combined with molecular quantitative analyses ( Figure 2 ; Table 1 ), we identified BCL2 protein in angioimmunoblastic T-cell lymphoma CD34
þ endothelial cells ( Figure 1 ) and showed a significantly higher expression of BCL2 mRNA in angioimmunoblastic T-cell lymphoma endothelial cells (3.27 ± 0.31) than in lymph node hyperplasia endothelial cells (1.34±0.17) (P ¼ 0.009). With the same methods used for lasermicrodissected CD3 þ CD10 þ lymphoma cells, we showed a significantly higher expression of BCL2 mRNA in angioimmunoblastic T-cell lymphoma cells (28.34 ± 2.34) than in lymph node hyperplasia CD3 þ lymphocytes (17.47 ± 1.07) (P ¼ 0.007). In the 30 patients with angioimmunoblastic T-cell lymphoma, 27.4 ± 5.3% of CD34 þ endothelial cells expressed CD105 neoangiogenic marker but were not detected in the eight patients with lymph node hyperplasia ( Figure 3) .
With BCL2/CD34/CD105 triple immunofluorescent labeling (Figures 4 and 5) , in the 30 patients with angioimmunoblastic T-cell lymphoma, BCL2 was only identified in CD34 þ CD105 þ neoangiogenic endothelial cells (Figures 4 and 5) . In these patients, 24.7±4.1% of CD34 þ endothelial cells were double positives for CD105 and BCL2 (Figure 3) .
To get further insight into BCL2 expression by angioimmunoblastic T-cell lymphoma endothelial cells, CD105
þ neoangiogenic endothelial cells were laser-microdissected and quantitative molecular analyses performed ( Figure 6 ; Table 1 ). There was a significantly higher expression of BCL2 mRNA in angioimmunoblastic T-cell lymphoma neoangiogenic CD105 þ endothelial cells (8.62±2.87) than in laser-microdissected CD34 þ endothelial cells (3.27 ± 0.31) (P ¼ 0.027). 
CD10
þ angioimmunoblastic T-cell lymphoma cells and CD3 þ lymph node hyperplasia lymphocytes (4.00±1.67 vs 0.51±0.06, P ¼ 0.012) ( Table 1) .
The coexpression of BCL2 and VEGFA in endothelial cells of angioimmunoblastic T-cell lymphoma was also confirmed qRT-PCR of laser-microdissected cells. BCL2 and VEGFA mRNA levels were significantly related in endothelial cells of angioimmunoblastic T-cell lymphoma (R 2 ¼ 0.745, Po0.0001), but not of lymph node hyperplasia (R 2 ¼ 0.091, P ¼ 0.2572). Moreover, BCL2 and VEGFA mRNA levels are not correlated in CD3 þ CD10 þ angioimmunoblastic T-cell lymphoma cells (R 2 ¼ 0.072, P ¼ 0.1602) (Figure 2c and d) .
AITL Endothelial BCL2 Expression and Tumor Progression
In the 30 angioimmunoblastic T-cell lymphoma cases (Table 1 ; Figure 7 ), endothelial BCL2 mRNA expression was not linked with proliferation index, but it was significantly related with (i) microvessel density, (ii) International Prognostic Index, 27 (iii) signs of tumor progression and extension (Bone marrow involvement, Ann Arbor Stage, elevated lactate dehydrogenase level). This contrasts with the absence of any clinical correlation with lymphoma cell BCL2 mRNA expression.
Further statistical analyses showed that BCL2 levels for CD34 þ and CD105 þ laser-microdissected angioimmunoblastic T-cell lymphoma endothelial cells correlated with the same clinical data. However, the statistical significance was higher for CD105 þ neoangiogenic endothelial cells than for CD34 þ endothelial cells regarding (i) microvessel density (R 2 ¼ 0.6412, Po0.0001 vs R 2 ¼ 0.5444, Within a median follow-up of 61 months, 17 patients (56%) relapsed and 16 of them (53%) died. The 2-year EFS and OS rate were, respectively, 41.3 and 72.9%, with median EFS and OS at 18.5 and 39 months. Poor EFS and OS were correlated with high BCL2 levels, in microdissected CD34 þ endothelial cells (P ¼ 0.0129 and 0.0231, respectively) and in microdissected CD34
þ CD105 þ neoangiogenic endothelial cells (P ¼ 0.0092 and 0.0104, respectively) but not in microdissected CD3 þ CD10 þ lymphoma cells (P ¼ 0.0612 and 0.0783, respectively).
Multivariate analyses revealed that BCL2 levels in microdissected CD34
þ CD105 þ neoangiogenic endothelial cells were independent adverse prognostic factors for event-free survival and overall survival (P ¼ 0.0091 and 0.0145, respectively).
Discussion
We showed the coexpression of BCL2 and VEGFA in endothelial and lymphoma cells of angioimmunoblastic T-cell lymphoma, and the significant relation of BCL2 expression in neoangiogenic endothelial cells with microvessel density, International Prognostic Index, and signs of tumor progression.
BCL2 overexpression is a hallmark of follicular lymphoma cells. 28 It has also been reported in lymphoma cells of few angioimmunoblastic T-cell lymphoma. 29 However, BCL2 overexpression in endothelial cells has not been reported so far in angioimmunoblastic T-cell lymphoma.
The role of BCL2 in endothelial cells has been demonstrated by experimental studies. The specific blocking of BCL2 activity by anti-BCL2 antisense G3139, alters in vitro endothelial cell growth and tubular morphogenesis. 12 In BCL2-deficient mice, isolated retinal endothelial cells have reduced capacities of migration, tenascin-C expression, and adhesion to vitronectin and fibronectin. They also fail to form capillaries in Matrigel. 30 On the contrary, experimental induction of BCL2 overexpression in HDMEC endothelial cells results in an enhanced angiogenic phenotype.
31
BCL2-transduction in HUVEC endothelial cells induces the formation of chimeric vessels, and arteriogenic remodeling in immunodeficient mice. 32 Moreover, the antiapoptotic activities of BCL2 correlate with vascular maturation and transcriptional modulation of HUVEC endothelial cells.
33
BCL2 and VEGFA proteins were coexpressed in endothelial and lymphoma cells of the 30 angioimmunoblastic T-cell lymphoma cases we studied. However, a significant relation between BCL2 and VEGFA mRNA levels was only found in endothelial cells. Controls with laser-microdissected endothelial cells from lymph node hyperplasia showed that this correlation between BCL2 and VEGFA mRNA levels was specific for angioimmunoblastic T-cell lymphoma endothelial cells. Such a correlation for endothelial cells but not for tumor cells has also been identified in oral squamous cell carcinoma, 8, 34 where in vitro studies further demonstrated that BCL2 expression level in endothelial cells controls VEGFA expression in tumor cells. 8 In xenografted squamous cell carcinoma cell lines, BCL2 crosstalk between endothelial and tumor cells through VEGFA leads to tumor growth and metastatic development. 8, 9, 11, 35 A neoangiogenic subtype of endothelial cells, expressing CD105, a TGFb-receptor type III auxiliary receptor, 13 has been identified. [36] [37] [38] CD105 expression on endothelial cells is related to tumor progression in squamous cell carcinoma, 16 glioblastomas, 15 and meningiomas. 14 It correlates with survival in primary central nervous system lymphomas. 17 In our study using immunostainings and laser-microdissection combined with molecular analyses, we demonstrate that in angioimmunoblastic T-cell lymphoma, only CD34 þ CD105 þ neoangiogenic endothelial cells expressed BCL2.
The fact that BCL2 expression by these neoangiogenic endothelial cells is significantly related with microvessel density in the 30 angioimmunoblastic T-cell lymphoma cases we studied is coherent with the role of VEGFA production by endothelial cells in tumoral angiogenesis. 39 The further significant relations of BCL2 expression by neoangiogenic endothelial with International Prognostic Index and signs of tumor extension, as well as an independent prognostic factor also underline the role of angiogenesis in lymphoma progression, a fact recently identified by stromal gene signatures in large-B-cell lymphomas. 40 Tumor development is characterized by a defective control of cellular homeostasis. The neoangiogenic endothelial BCL2 positives relations with International prognostic Index and signs of tumor extension, as well as an independent prognostic factor, and the absence of relation with the global Proliferation Index (i.e., stromal and tumoral cells) can be interpreted as an antiapoptotic action of neoangiogenic endothelial BCL2 on lymphoma cells. þ endothelial cells from angioimmunoblastic T-cell lymphoma lymph node, BCL2 mRNA expression level is significantly correlated with microvessel density (left). In CD105
þ neoangiogenic endothelial cells of angioimmunoblastic T-cell lymphoma, BCL2 mRNA expression is highly related with microvessel density. In contrast, BCL2 CD34 þ endothelial mRNA level is not correlated with microvascular density in reactive lymph node hyperplasia. (b) In AITL, CD34 þ endothelial as well as CD105 þ neoangiogenic endothelial cell BCL2 mRNA levels are not correlated with KI67 proliferating index. In CD34 þ endothelial cells of lymph node hyperplasia, no correlation was observed either.
